Masterclass series in peripheral arterial disease

Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-1353.

Asherson RA , Cervera R , Piette J-C. Catastrophic antiphospholipid syndrome: clinical and laboratory features in 50 patients. Medicine 1999; 77: 195-207.

Lockshin MD , Sammaritano LR , Schwartzman S. Value of Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2002; 44: 1965-1966.

Galli M , Comfurius P , Maassen C et al. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.

Malia RG , Kitchen S , Greaves M , Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-107.

Pierangeli SS , Colden-Stanfield M , Liu X , Barker JH , Anderson GL , Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 1997-2002.

Amengual O , Atsumi T , Khamashta MA , Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-281.

Khamashta MA , Cuadrado MJ , Mujic F , Taub NA , Hunt BJ , Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.

Crowther MA , Ginsberg JS , Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid syndrome. N Engl J Med 2003; 349: 1133-1138.

Rai R , Cohen H , Dave M , Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-257.

Farquharson RG , Quenby S , Greaves M. Antiphospholipid syndrome in pregnancy: a randomised, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-413.

Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471-1478.

Landolfi R , Marchioli R , Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997; 78: 617-621.

Spivak JL. The optimal management of polycythaemia rubra vera. Br J Haematol 2003; 120: 543-554.

Murphy S. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis and leukaemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 1997; 78: 622-626.

Landolfi R , Marchioli R , Kutti J et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-124.

Spivak J. Daily aspirin - only half the answer. N Engl J Med 2004; 350: 99-101.

Bernard GR , Vincent JL , Laterre PF et al. Efficacy and safety of recombinant activated protein C in severe sepsis. N Engl J Med 2001; 344: 699-709.